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Abstract: Despite the status of chronic obstructive pulmonary disease (COPD) as a major global 
health problem, no currently available therapies can limit COPD progression. Therefore, an 
urgent need exists for the development of new and effective treatments for COPD. An improved 
understanding in the molecular pathogenesis of COPD can potentially identify molecular targets 
to facilitate the development of new therapeutic modalities. Among the best approaches for 
understanding the molecular basis of COPD include gene expression proﬁ  ling techniques, such 
as serial analysis of gene expression or microarrays. Using these methods, recent studies have 
mapped comparative gene expression proﬁ  les of lung tissues from patients with different stages 
of COPD relative to healthy smokers or non-smokers. Such studies have revealed a number of 
differentially-regulated genes associated with COPD progression, which include genes involved 
in the regulation of inﬂ  ammation, extracellular matrix, cytokines, chemokines, apoptosis, and 
stress responses. These studies have shed new light on the molecular mechanisms of COPD, 
and suggest novel targets for clinical treatments.
Keywords: COPD, gene expression, therapeutic targets
Introduction
Chronic obstructive pulmonary disease (COPD) is a major global health problem 
predicted to rank as the third greatest cause of mortality by the end of the next decade 
(Lopez and Murray 1998). COPD is a slowly progressive and poorly reversible inﬂ  am-
matory disease characterized by the functional abnormality of airway obstruction, 
which includes emphysema, chronic bronchitis, and small airways disease (Pauwels 
et al 2001). Cigarette smoking is the most important risk factor for the development 
of COPD. However, only 10%–15% of smokers develop the disease, implying genetic 
factors may increase the risk in certain individuals (Mayer and Newman 2001). Smok-
ing cessation is the most efﬁ  cient therapeutic intervention so far shown to reduce the 
disease progression (Barnes 1999, 2004). However, the poor long-term success rate of 
smoking cessation (16% at 6 months) requires the development of still more effective 
approaches (Barnes 2004). A number of experimental therapeutics have been studied 
for their potential in COPD treatment or prevention, which include antioxidants, anti-
inﬂ  ammatory agents, and/or small molecule inhibitors of proinﬂ  ammatory signaling 
pathways, thus far with limited success (Barnes and Stockley 2005).
The lack of drug development for this disease is due to the relatively recent emer-
gence of research addressing the molecular and cellular basis of COPD (Barnes et al 
2003; Barnes 2005; Barnes and Hansel 2004; Donnelly and Barnes 2006; Yoshida 
and Tuder 2006). A general scheme of the molecular pathways involved in COPD 
pathogenesis and potential areas for therapeutic intervention is shown in Figure 1.
Gene expression proﬁ  ling of human diseased tissues may provide insights into the 
molecular mechanisms of human disease and may eventually lead to the identiﬁ  ca-
tion of novel therapeutic targets. The goal of this article is to summarize recent gene International Journal of COPD 2008:3(3) 360
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expression proﬁ  ling studies in COPD, and to integrate the 
ﬁ  ndings with biochemical observations in COPD/emphysema 
pathogenesis and drug development.
Gene expression proﬁ  ling studies
in emphysema/COPD
Recent studies have analyzed lung gene expression proﬁ  les 
of COPD patients at different stages of disease progression 
relative to control subjects (Golpon et al 2004; Ning et al 
2004; Spira et al 2004; Pierrou et al 2007; Wang et al 2008). 
Two general approaches have been applied with respect to 
sample generation: the analysis of total lung homogenates 
and the analysis of discrete cell populations. While both 
approaches are valid, they each have some limitations. 
Analysis of whole lung homogenates provides a global view 
of lung gene expression proﬁ  les, but due to the heterogeneous 
nature of the lung, signals originating in one cell type may be 
diluted by cell populations which do not respond in the same 
way. Furthermore, signals speciﬁ  c to specialized or rare cell 
populations may not be detectable. Detectable increases in 
gene expression can be localized to speciﬁ  c cell types by sub-
sequent validation with real-time polymerase chain reaction 
(RT-PCR) or immunohistochemical approaches. The analysis 
of discrete cell populations by microarray will provide a 
clearer understanding of the response in individual cell types, 
but at the same time may overlook signiﬁ  cant responses of 
the lung as a whole. The latter approach is technically more 
challenging, and requires the preparation of relatively pure 
samples, sometimes requiring advanced techniques such as 
laser capture microdissection.
Golpon and colleagues (2004) characterized differential 
gene expression in total lung homogenates between advanced 
emphysema and healthy human subjects, and also compared 
“usual” emphysema with α1-antitrypsin (α1-AT) deﬁ  ciency, 
Figure 1 Molecular Mechanisms in COPD pathogenesis and potential therapeutic targets.   A number of signaling pathway components have been identiﬁ  ed which regulate 
apoptosis, inﬂ  ammation and ﬁ  brosis potentially associated with COPD pathogenesis. Many of these have been identiﬁ  ed as possible targets for therapeutic intervention using 
small molecule inhibitors or antagonists.
Abbreviations: COPD, chronic obstructive pulmonary disease; ECM, extracellular matrix; Egr-1, early growth response-1; HDAC, histone deacetylase; HO-1, heme oxygenase-1; 
Keap-1, Kelch-like ECH associating protein-1; MMP, matrix metalloproteinase; NF-κB, nuclear factor-kappa-B; Nrf-2, nuclear factor-E2-related factor-2; p38 MAPK, p38 mitogen-
activated protein kinase; ROS, reactive oxygen species; TGFβ1, transforming growth factor-Β1.
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the genetic cause of emphysema. Lungs with severe emphy-
sema displayed decreases in overall global gene expression, 
with pronounced increases in transcripts encoding pro-
inﬂ  ammatory mediators, immune-response proteins, and 
proteolytic enzymes. Many of these differentially-expressed 
genes were also observed in α1-AT lung, which displayed an 
additional set of differentially-regulated genes involved in 
protein synthesis, energy metabolism, and immune function. 
The authors concluded that the two types of emphysema can 
be distinguished from each other, and from normal tissue by 
gene expression proﬁ  les (Golpon et al 2004).
Ning and colleagues (2004) analyzed gene expression 
proﬁ  les in total lung tissue obtained from COPD patients 
(GOLD2) that were smokers vs GOLD0 smokers, using 
serial analysis of gene expression (SAGE) and comparative 
microarray analysis. Analysis of the same RNA sample 
set revealed 327/261 differentially-expressed transcripts 
by SAGE or microarray, respectively. The genes differen-
tially expressed in GOLD2 vs GOLD0 were identiﬁ  ed as 
belonging to several functional classes, including transcrip-
tion factors, growth factors, cytokines, chemokines, and 
extracellular matrix (ECM) proteins. For example, analysis 
of GOLD2 smoker’s lungs tissue revealed upregulation of 
transcripts for pro-inﬂ  ammatory mediators, (eg, TGFβ-1, 
CX3CL1, CTGF, CYR61, TNFSF10, and the interleukin-1 
receptor), relative to GOLD0 smokers. Additionally, Egr-1 
was identiﬁ  ed as a major pro-inﬂ  ammatory transcriptional 
regulator that was upregulated in GOLD2 vs GOLD0 lung 
tissue. On the other hand, lung tissue from GOLD0 smokers 
displayed higher levels of expression of transcripts encoding 
ECM proteins (eg, collagens), relative to GOLD2 smokers. 
This study reported a high level of agreement between SAGE 
and microarray analyses of the same sample set, in particular 
with respect to the expression of inﬂ  ammatory mediators and 
ECM proteins (Ning et al 2004).
Using high-density microarrays, Spira and colleagues 
(2004) evaluated gene expression in lung tissues from 
patients with severe emphysema, removed during lung 
reduction surgery, relative to tissues from patients with mild 
emphysema undergoing surgical resection of lung nodules, 
or normal smokers. From this analysis, 102 genes were 
identiﬁ  ed whose differential expression distinguished severe 
emphysema from mildly emphysematous or normal tissue. 
This analysis revealed the upregulation of many ECM-related 
proteins and the downregulation of immune-function and 
cell signaling-related genes in severe vs mild emphysema 
(Spira et al 2004). Furthermore, this study identiﬁ  ed subsets 
of genes whose expression were positively or negatively 
correlated with decline of lung functional parameters (Spira 
et al 2004).
A more recent study compared surgically resected lung 
tissue from nonsmokers with lung tissues from COPD 
patients at GOLD stages 0–3 (Wang et al 2008). Mor-
phometric analysis of samples revealed a subset of genes 
whose expression varied with the sample composition (% 
parenchyma). Furthermore 203 genes were identiﬁ  ed whose 
expression correlated to lung function. This analysis revealed 
the upregulation of ECM-related genes and apoptosis genes, 
and the downregulation of anti-inﬂ  ammatory genes in COPD 
tissues (Wang et al 2008).
Pierrou and colleagues (2007) evaluated differential gene 
expression in bronchial epithelial cell brushings taken from 
COPD smokers, healthy smokers and healthy nonsmok-
ers, with a microarray analysis focused on oxidative stress 
genes. A large number of genes involved in oxidative stress 
responses were differentially expressed by smoking relative 
to nonsmoking controls, with metallothioneins prominently 
expressed. An additional set of genes were differentially 
regulated in COPD patients relative to healthy smokers. 
These included thioredoxins, superoxide dismutase-2, and 
genes involved in energy metabolism, respiration, and 
apoptosis. Analysis of both comparisons (COPD smokers 
vs healthy smokers, and healthy smokers vs nonsmokers) 
revealed a common set of upregulated genes that included 
cytochrome p 450 isozymes and aldo-keto reductases. Among 
those genes downregulated in healthy smokers, but upregu-
lated at an early stage of COPD (GOLD0-1), a trend toward 
decreased expression with increasing disease severity was 
noted for the later stages of COPD (GOLD2-4). Microarray 
analysis was also performed on primary human bronchial 
epithelial cells derived from the same subjects and exposed 
to in vitro cigarette smoke, and these results were conﬁ  rma-
tory of those obtained from healthy smokers vs nonsmokers 
(Pierrou et al 2007).
There was little apparent overlap between speciﬁ  c gene 
sets between the various studies. However some similarities 
were observed in the functional categories of differentially 
expressed genes, with variations in ECM related proteins and 
inﬂ  ammatory regulators the most common (Table 1).
A primary difference between the human gene expression 
proﬁ  ling studies was the use of epithelial cell brushings in the 
study of Pierrou and colleagues (2007), vs total lung tissue in 
the studies of Spira (2004); Ning (2004); and Wang (2008) 
and their colleagues. Wang (2008) represented a much more 
heterogeneous lung cell population. The studies by Wang and 
colleagues (2008) demonstrated that variations in sample International Journal of COPD 2008:3(3) 362
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content can dramatically inﬂ  uence gene expression results. 
In addition to sample type and composition, variations in 
sample acquisition techniques, degree of disease severity, 
exclusion criteria, and microarray platforms may account in 
part for these differences (Wang et al 2008).
In animal models of smoke exposure, a recent study has 
compared the gene expression proﬁ  les of rat lungs exposed to 
acute and chronic cigarette smoking (Stevenson et al 2007). 
Rats were exposed to cigarette smoke for various intervals 
up to 8 months. This study identiﬁ  ed an early acute phase of 
differential gene expression associated with initial responses 
to smoke exposure, followed by a chronic phase of gene 
expression associated with the development of pathologi-
cal changes resembling COPD, including neutrophil inﬂ  ux, 
inﬂ  ammation and emphysematous changes. Among the early 
differentially expressed genes in response to acute smoke 
exposure included several associated with major metabolic 
pathways including glycolysis and oxidative phosphoryla-
tion. The early acute phase displayed upregulation of stress 
proteins such as heme oxygenase-1 (HO-1), thioredoxin, 
manganese superoxide dismutase (MnSOD) and detoxiﬁ  ca-
tion related genes, as well as a major transcriptional regula-
tor associated with acute stress responses, NF-E2 related 
factor-2, (Nrf-2). These results were indicative of increased 
energy demand and adaptive responses of pulmonary cells 
exposed to acute smoke. The early chronic phase (2–3 weeks) 
was associated with increased expression of ECM related 
proteases (ie, MMP-12), cytokines, chemokines, and stress 
response proteins. Persistent activation of stress proteins 
was also observed in rats acutely exposed to smoke followed 
by smoking cessation. The late chronic phase (8 months) 
was associated with major alterations in genes involved in 
immune regulation (Stevenson et al 2007).
Collectively, these human and animal gene expression 
proﬁ  ling studies have suggested several novel candidate 
therapeutic targets, as outlined in the following sections.
Apoptosis/cell cycle arrest
The lung consists of a heterogenous population of diverse cell 
types. These include epithelial cells which form the lining 
of the airway, bronchii, and alveoli, interstitial ﬁ  broblasts 
which provide lung structure, endothelial cells which line the 
pulmonary vasculature; and smooth muscle cells that provide 
the contractility of the airway and pulmonary vasculature. 
Furthermore the lung contains resident inﬂ  ammatory cells 
such as alveolar macrophages.
Recent studies of lung tissues from COPD patients have 
revealed the presence of apoptotic cells in greater numbers 
than in control lungs or those from smokers without COPD 
(Henson et al 2006). Among those cells which undergo 
apoptosis in situ include alveolar and bronchial epithelial 
cells as well as endothelial cells in the parenchyma. In 
rodents, induction of endothelial or epithelial cell apoptosis 
is accompanied by loss of pulmonary alveoli and pathological 
evidence of emphysematous changes (Kasahara et al 2000). 
Blockade of the vascular endothelial growth factor receptors 
caused epithelial cell apoptosis, oxidative stress and emphy-
sema-like disease in rats and mice (Petrache et al 2005). In 
addition, lung ﬁ  broblasts from patients with emphysema 
show a reduced proliferation rate (Nobukuni et al 2002). 
Cigarette smoke induces cellular senescence and cell cycle 
arrest in lung ﬁ  broblasts (Nyunoya et al 2006). This evidence 
suggests that apoptosis and cell cycle arrest may play crucial 
roles in emphysema and COPD. Gene expression proﬁ  ling in 
emphysema revealed that many apoptosis/cell cycle-related 
genes were tightly correlated with lung function as assessed 
by the forced expiratory volume in one second (FEV1) (Spira 
et al 2004). The gene expression proﬁ  ling studies of Ning and 
colleagues (2004) observed increased expression of apoptosis 
related factors and of inhibitors of cellular proliferation (eg, 
CDKN1A and CDC2L1) in GOLD2 COPD lung relative 
to GOLD0 samples, and furthermore, that mitochondrial 
function-related genes were signiﬁ  cantly downregulated 
in COPD lungs. Collectively, these studies suggest that 
inhibition of smoking-induced apoptosis/cell cycle arrest 
may have a therapeutic value in COPD prevention. Although 
therapeutic agents targeting apoptosis pathways are cur-
rently starting to emerge in biomedical research and human 
clinical trials (eg, for cancer therapy), we have yet to observe 
the translational application of these targets in COPD. 
However, with improved understanding in the mechanism 
of smoke induced cell death and apoptosis of critical lung 
cells important in tissue repair and remodeling, one could 
envision how anti-apoptotic agents could mitigate lung 
epithelium cell death in susceptible smokers with epithelial 
cell injury and cell death.
Inﬂ  ammation
Chronic inﬂ  ammation has been well recognized as a primary 
characteristic of COPD. Inhibition of the inﬂ  ammatory 
response may represent an important therapeutic strategy for 
COPD. Gene expression proﬁ  ling has identiﬁ  ed a number of 
inﬂ  ammation-related proteins that are modulated in COPD, 
including adhesion molecules, as well as signaling molecules 
and transcription factors known to regulate pro-inﬂ  ammatory 
processes, as outlined below. Anti-inflammatory drugs International Journal of COPD 2008:3(3) 364
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directed against these molecular targets are currently under 
development.
Adhesion molecules
Recruitment and activation of inﬂ  ammatory cells is an impor-
tant event in the pathogenesis of COPD. The adherence of 
neutrophils, monocytes, and cytotoxic T-cells to the vascular 
wall and subsequent recruitment into the lungs and respira-
tory tract is dependent on adhesion molecules expressed by 
these cells and on endothelial cells in the pulmonary and 
bronchial vasculatures (Barnes 2005). The expression of 
macrophage associated antigen-1 (Mac-1) is increased on 
neutrophils of patients with stable COPD, suggesting that 
targeting such adhesion molecules may have therapeutic 
potential (Noguera et al 1998). The expression of leukocyte 
as well as epithelial/endothelial surface adhesion molecules 
was elevated in resected lung tissue from heavy smokers, 
consistent with an inﬂ  ammatory response to lung inﬂ  am-
mation but not correlated to the degree of airways obstruc-
tion (Gonzalez et al 1996). Increased levels of circulating 
intercellular adhesion molecule-1 (cICAM-1) and circulat-
ing E-selectin (c-E-selectin) in serum, and of cICAM-1 in 
BAL, were observed in COPD patients relative to controls. 
The serum levels of c-E-selectin correlated signiﬁ  cantly 
with lung function (Riise 1994). Gene expression proﬁ  ling 
studies have indicated that adhesion molecules occur among 
the classes of genes that are up-regulated in the total lung 
tissue of COPD patients compared with healthy smokers 
(Ning et al 2004).
Selectin-mediated adhesion of leukocytes to the vascu-
lar endothelium is a key early event in the initiation of the 
inﬂ  ammatory response, and therefore selectin may represent 
a valid target for therapeutic intervention (Romano 2005). 
Several adhesion molecules can now be inhibited pharma-
cologically, and among these inhibitors, bimosiamose is the 
leading selectin inhibitor in clinical development (Davenpeck 
et al 2000; Romano 2005).
Cytokines and chemokines
The inﬂ  ammatory response associated with COPD involves 
multiple cytokines which regulate the activation, prolifera-
tion, and differentiation of inﬂ  ammatory cells. The recruit-
ment of inﬂ  ammatory cells to the lung including neutrophils, 
monocytes, eosinophils, and CD8+ cytotoxic T-cells, is 
orchestrated by chemokines that are released from alveolar 
macrophages and pulmonary epithelial cells. In exhaled 
breath condensate, healthy smokers displayed increased 
levels of interleukins (IL), such as IL-1β, IL-6, IL-8, IL-10 
and IL-12p70, and tumor necrosis factor alpha (TNF-α) when 
compared with nonsmokers, and all cytokines were increased 
on COPD exacerbations when compared with patients with 
stable COPD (Gessner et al 2005). TNF-α was increased in 
smoker’s serum and sputum samples (Keatings et al 1996). 
The neutrophil chemokines IL-8 (CXCL8) and growth related 
oncogene-alpha (GROα), as well as the monocyte chemotac-
tic protein-1 (MCP-1) were also increased in sputum from 
COPD patients (Yamamoto et al 1997; Traves et al 2002) 
and negatively correlated with lung function. In agreement 
with these observations, gene expression proﬁ  ling revealed 
that many inﬂ  ammatory cytokine (ie, TNF-α receptors and 
interleukin receptors), and chemokine-related genes (ie, 
fractalkine/CX3CL1) were signiﬁ  cantly increased in COPD 
patients (Ning et al 2004).
Strategies involving modulation of cytokine or cyto-
kine receptor gene expression may have future potential 
for COPD therapy, as suggested by recent experiments in 
animal models. For example, transgenic overexpression of 
TNF-α led to emphysema and exaggerated alveolar inﬂ  am-
mation (Fujita et al 2001), whereas TNF-α receptor knockout 
mice showed signiﬁ  cant protection against cigarette smoke 
induced emphysema (Churg et al 2004). The IL-1 receptor/
TNF-α receptor double knockout mice were protected against 
elastase-induced emphysema (Lucey et al 2002).
Chemokine receptor blockade using small molecule 
antagonists has also been proposed as an anti-inﬂ  ammatory 
strategy with potential applications in COPD (Donnelly 
and Barnes 2006). The chemokine receptors implicated in 
COPD, include CXCR1 and CXCR2 which are expressed on 
monocytes and neutrophils; CXCR3, which is expressed on 
T-cell and B-cells; and receptors of the CCR series (−1, −2, −3, 
−5) which are expressed on various leukocytes (Donnelly and 
Barnes 2006). Several CXCR2 antagonists have been shown 
to reduce neutrophil inﬂ  ux in animal models in response to 
proinﬂ  ammatory stimuli or cigarette smoke exposure (Hay 
and Sarau 2001; Stevenson et al 2005; Thatcher et al 2005). 
Recent human clinical studies have shown promise for CCR1 
antagonists in reducing inﬂ  ammation associated with rheu-
matoid arthritis (Haringman 2003). Future investigations and 
clinical trials have yet to reveal the effectiveness of this class 
of pharmaceuticals in human COPD (Barnes 2005).
NFκB
The expression of many of chemokines such as IL-8/CXCL8 
and cytokines such as TNFα is regulated by transcription fac-
tor, NFκB, a pleiotropic regulator of inﬂ  ammatory processes 
(Figure 2) (Yagi et al 2006; Yang et al 2006). NFκB is   in mac-International Journal of COPD 2008:3(3) 365
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rophages and epithelial cells of COPD patients (Di Stefano 
et al 2002; Caramori et al 2003). Szulkaowski and colleagues 
(2006) examined the proteosomal degradation of IκBα and 
NFκB DNA binding activity in the human lung in response to 
cigarette smoking. IκBα levels were signiﬁ  cantly decreased 
while NFκB DNA binding was signiﬁ  cantly increased in 
healthy smokers and current smokers with moderate COPD, 
compared with healthy nonsmokers (Szulkaowski et al 2006). 
Analysis of transcription factor binding sites occurring in the 
promoter regions of differentially-expressed genes revealed 
that NFκB sties were overrepresented among those genes that 
were downregulated by smoking (relative to nonsmokers) and 
upregulated by COPD (relative to healthy smokers) (Pierrou 
et al 2007). These observations, taken together, suggest that 
modulation of NFκB activity may represent a potential target 
in COPD therapy. There are several approaches to inhibition 
of NFκB, including gene transfer of its inhibitor protein IκB, 
and small-molecule inhibitors of IκB-kinase (IKK) (Newton 
et al 2007).
p38 MAPK
A large number of inﬂ  ammatory response-related signal 
transduction molecules are modulated in COPD patients, 
including mitogen-activated protein kinases (MAPK) and 
related proteins (Golpon et al 2004; Ning et al 2004). MAPK 
play an important role in chronic inﬂ  ammation (Johnson et al 
2002) (Figure 2). Indeed, activation of members of the MAPK 
family triggers the activation of several transcription factors, 
including NFκB. This eventually results in the expression of 
a battery of distinct genes that can regulate pro-inﬂ  ammatory, 
pro-apoptotic and antiproliferative responses (Johnson 2002). 
Among these, the p38 MAPK pathway is activated by cellular 
stress and regulates the expression of inﬂ  ammatory cytokines, 
including IL-8, TNFα, and matrix metalloproteases (MMPs) 
(Meja 2000). Inhibitors of the p38 MAPK family have been 
shown to exert anti-inﬂ  ammatory effects in preclinical disease 
models, primarily through the inhibition of the expression of 
inﬂ  ammatory mediators (Lee et al 2005). Several promis-
ing compounds have also progressed to clinical trials. One 
of these, SB239063, can reduce neutrophil inﬁ  ltration after 
inhaled endotoxin and lower the concentrations of IL-6 and 
MMP9 in bronchoalveolar lavage ﬂ  uid of rats, suggesting a 
potential role in COPD treatment (Underwood et al 2000).
Histone deacetylases
Many factors, including speciﬁ  c DNA sequences, histones, 
nonhistone chromosomal proteins, transcriptional activators/
repressors and the transcriptional machinery, are all 
necessary for the establishment of an active transcription 
complex. Histone acetytransferases (HAT) and histone 
deacetylase (HDAC) are families of enzymes that regulate 
chromatin structure and thereby affect inﬂ  ammatory gene 
expression (Barnes et al 2005). Acetylation of core histones 
by coactivator proteins that possess intrinsic HAT activity 
leads to unwinding of chromatin, which subsequently allows 
transcription factors and RNA polymerase II to activate 
gene transcription. Conversely, deacetylation of core his-
tones by HDAC is generally associated with transcriptional 
repression.
Recent evidence has suggested an important role for 
HDAC activity in COPD. Surgically resected lung tissue 
from nonsmokers or GOLD0-4 smokers, showed signiﬁ  cant 
decreases of HDAC activity in COPD lung tissue relative to 
nonsmokers whose magnitude correlated with disease sever-
ity and inﬂ  ammatory gene expression (Ito et al 2005). In 
addition to lung tissue, HDAC activity was also decreased in 
alveolar macrophages from BAL samples of COPD patients 
(Ito et al 2005). Furthermore, the expression of HDAC2 
Figure 2 Epigenetic factors involved in the regulation of inﬂ  ammation.
Abbreviations: HDAC, Histone deacetylase; I-κB, Inhibitor of NF-κB; IKK, I-κB 
kinase; MKKK, mitogen-activated protein kinase-3; MKK3/6, mitogen-activated protein 
kinase kinase-3/6; NF-κB, nuclear factor-kappa-B; p-I-κB, phospho-I-κB; p38 MAPK, 
p38 mitogen-activated protein kinase; ROS, reactive oxygen species.
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mRNA and protein in peripheral lung tissue and BAL mac-
rophages, declined as a function of disease progression (Ito 
et al 2005).
Cells exposed to cigarette smoke extract (CSE) also 
exhibit decreased HDAC activity and protein levels, and this 
process appears to be redox-dependent (Yang et al 2006). In 
rats exposed to cigarette smoke, HDAC2 activity and protein 
expression signiﬁ  cantly decreased at 3 days of treatment, 
while histone-3 phospho-acetylation and histone-4 acetyla-
tion increased at 8 weeks of treatment (Marwick et al 2004). 
Consistent with these ﬁ  ndings, our gene proﬁ  ling results also 
revealed that certain histones were increased in COPD and 
that HDAC2 was signiﬁ  cantly decreased (Ning et al 2004). 
All these ﬁ  ndings could explain therapeutic refractoriness and 
perpetuation of HDAC and could reveal an evolving thera-
peutic target in COPD. For example, theophylline restores 
histone deacetylase activity and steroid responses in COPD 
macrophages, suggesting potential application of this drug 
in COPD therapy (Cosio et al 2004).
Egr-1
Among the thousands of genes differentially expressed in 
COPD, Egr-1 mRNA is one of the signiﬁ  cantly up-regulated 
transcripts identiﬁ  ed by both SAGE and microarray analysis 
with conﬁ  rmation by RT-PCR and immunohistochemical 
approaches (Ning et al 2004). Egr-1 is a zinc ﬁ  nger transcrip-
tion factor classiﬁ  ed as an immediate-early response protein, 
which is potentially induced by a variety of cellular stressors 
(Lee et al 1996). As a major transcription factor, Egr-1 
regulates the expression of a large number of genes, includ-
ing repair enzyme systems, angiogenic factors, cytokines, 
apoptotic factors, cell cycle factors, metabolic factors and 
proteases (Yan et al 2000). Ning et al observed that exposure 
to aqueous cigarette smoke extract (CSE) treatment could 
stimulate Egr-1 expression and transcriptional activity in 
human lung ﬁ  broblasts. In addition, matrix metalloproteinase 
(MMP)-2 and MMP-9 activities were modulated in an Egr-1-
dependent manner in mouse lung ﬁ  broblast cells treated with 
cytomix (Ning et al 2004). These data suggest that Egr-1 may 
serve as a potentially important molecule, which could play 
a key role in development of cigarette smoke-related COPD 
by regulating MMP activity and subsequently accelerating 
the turnover of ECM proteins.
Protease/antiprotease imbalance
A central hypothesis for the development of emphysema is 
that various proteases break down connective tissue com-
ponents in lung parenchyma (Barnes et al 2003). Increased 
proteolysis in the lung leads to aberrant remodeling and/or 
degradation of the ECM. Thus, altered ECM deposition con-
tributing to airway wall remodeling is an important feature 
of asthma and COPD. A large number of ECM-related genes 
were up-regulated in the lungs of smokers with emphysema, 
and those were correlated to the FEV1 (Spira et al 2004). 
Inhibition of these proteolytic enzymes or an increase in 
endogenous antiproteinases should therefore be beneﬁ  cial 
and theoretically should prevent the progression of airﬂ  ow 
obstruction in COPD. Among those proteases, neutrophil 
elastase, MMPs, and cathepsins are the most studied candi-
dates that account for the protease/antiprotease imbalance 
in COPD.
The evidence in support of a signiﬁ  cant role of neutro-
phil elastase in the pathogenesis of emphysema has relied 
on the ﬁ  nding of early emphysema in patients deﬁ  cient in 
α1-antitrypsin, the major inhibitor of neutrophil elastase. 
Emphysema caused by lung instillation of porcine pancreatic 
elastase has been a disease model widely used in support of 
the protease/antiprotease imbalance over the past 30 years 
(Yoshida et al 2007). Neutrophil elastase is a neutral serine 
protease and is a major constituent of lung elastolytic activity. 
It also potently stimulates the secretion of mucus and induces 
IL-8 release from epithelial cells and therefore may perpetu-
ate the inﬂ  ammatory stage. Neutrophil elastase null mice 
were signiﬁ  cantly protected against chronic cigarette smoke 
induced emphysema, which was associated with decreased 
MMP-12 activation and increased tissue inhibitor of matrix 
metalloproteinase activity (Shapiro et al 2003). Several drugs 
have been shown to inhibit neutrophil elastase-induced lung 
injury in experimental animals, and to inhibit neutrophil 
elastase-induced secretion of mucus in vitro (Williams et al 
1991; Ohbayashi 2002).
There is substantial evidence of increased expression of 
several MMPs in emphysematous lungs. MMPs are a fam-
ily of proteolytic enzymes that have a number of important 
physiological roles including remodeling of the extracellular 
matrix, facilitating cell migration, cleaving cytokines, and 
activating defensins. However, excess MMP activity may 
lead to tissue destruction. MMPs have been suggested as the 
major proteolytic enzymes involved in the pathogeneses of 
COPD because these proteins are a unique family of metal-
loenzymes that, once activated, can destroy connective 
tissue. MMP-12 activation has been a leading candidate 
proteinase responsible for pulmonary emphysema, because it 
is predominantly produced by alveolar macrophages and can 
degrade elastin. There is abundant evidence linking MMP-12 
and experimental emphysema (Yoshida et al 2007). MMP-12 International Journal of COPD 2008:3(3) 367
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null mice are protected from the development of cigarette 
smoke induced emphysema (Hautamaki et al 1997). Recent 
data indicate that the use of selective inhibitors of MMPs 
might lead to new therapies for acute and chronic inﬂ  amma-
tory diseases (Cataldo et al 2003; Whelan 2004).
Gene expression proﬁ  ling also revealed that multiple 
cathepsins were increased in COPD lung tissues (Ning et al 
2004; Spira et al 2004). Cathepsin G has elastolytic activity. 
Cathepsins B, L, and S are also released from macrophages. 
In cigarette smoke-exposed mice, cathepsin D was highly 
expressed in pulmonary macrophages and dendritic cells 
(Bracke 2005). Inducible targeting of IL-13 to the adult lung 
causes matrix metalloproteinase- and cathepsin-dependent 
emphysema (Zheng et al 2000). These ﬁ  ndings suggest that 
cathepsin inhibitors might be a useful approach for COPD 
therapy.
Fibrosis
While apoptosis is implicated in epithelial cell death and 
alveolar destruction leading to emphysema, increased ﬁ  bro-
blast proliferation may account for small airways disease also 
present in COPD (Yoshida and Tuder 2007). Recent studies 
have shown that ﬁ  brosis and COPD can coexist in the same 
patient (Gauldie et al 2006). The transforming growth factor 
(TGF)-β1 is highly expressed in epithelium and macrophages 
of small airways of smokers with COPD (de Boer et al 1998; 
Takizawa et al 2001), suggesting a role for TGF-β1 in the 
development of COPD. TGF-β1 is a pleiotropic cytokine 
with a wide variety of effects on cellular proliferation, dif-
ferentiation, and inﬂ  ammation. TGF-β1 may be important 
in inducing the ﬁ  brosis and narrowing of peripheral airways 
(obstructive bronchiolitis) in COPD. Gene expression proﬁ  l-
ing revealed that TGF-β1 and its regulatory pathways were 
signiﬁ  cantly increased in COPD patients (Ning et al 2004; 
Wang et al 2008). Thus, inhibition of TGF-β1 signaling may 
be a useful therapeutic strategy in COPD. Small molecule 
antagonists that inhibit TGF-β1-receptor kinase are now 
under development (Ishikawa et al 2003; Akhurst 2006).
Oxidative stress
Cigarette smoke is a rich source of oxidants. Accumulating 
evidence has shown increased oxidative stress in smokers 
(Pierrou et al 2007), as revealed by the increased concentra-
tions of H2O2 in exhaled breath (Horvath et al 2004), and 
other markers including lipid peroxidation end-products 
(Lapenna et al 1995), oxidatively modiﬁ  ed protein (Pignatelli 
et al 2001), and DNA damage (Cuzick et al 1990). In COPD 
patients, exhaled biomarkers of lipid peroxidation such as 
8-isoprostane (Biernacki 2003) and ethane (Paredi et al 2000) 
are signiﬁ  cantly increased. Gene proﬁ  ling studies also show 
that the expression of redox/stress related genes are tightly 
correlated with the FEV1 and carbon monoxide lung diffusion 
capacity (DLCO) (Spira et al 2004), and that several major 
antioxidant enzymes such as glutaredoxin and catalase are 
decreased in COPD by 5-fold compared with healthy smok-
ers (Ning et al 2004). Genetic ablation of Nrf2, a pivotal 
transcriptional factor regulating the expression of many 
antioxidant enzymes, enhances susceptibility to cigarette 
smoke-induced emphysema (Rangasamy et al 2004), and 
severe airway inﬂ  ammation and asthma in mice (Rangasamy 
et al 2005). Analysis of transcription factor binding sites 
occurring in the promoter regions of differentially expressed 
genes revealed that Nrf2 sties were overrepresented among 
those genes that were both upregulated by smoking (rela-
tive to nonsmokers) and upregulated by COPD (relative to 
healthy smokers) (Pierrou et al 2007). Enhancement of cel-
lular antioxidant capacity has been suggested as a possible 
target for COPD therapy. Effective antioxidants including 
stable glutathione analogs, superoxide dismutase mimics, and 
selenium-based drugs, are now in development for clinical 
use (MacNee 2000).
Heme oxygenase-1
Heme oxygenase-1 (HO-1) is a major inducible stress protein 
of mammalian cells and tissues. HO-1 expression confers 
cytoprotection in a variety of tissue injury and disease mod-
els (Ryter et al 2006), among which include experimental 
elastase-induced emphysema (Shinohara et al 2005). Recent 
studies have revealed that HO-1 is highly induced by cigarette 
smoke exposure protocols, including mainstream smoke, 
cigarette smoke condensate, and aqueous cigarette smoke 
extract (CSE) in a number of cell types (Knorr-Wittmann et al 
2005; Fukano et al 2006a, 2006b; Palozza et al 2006). We 
have shown that CSE induces HO-1 in bronchial and other 
pulmonary epithelial cell types exposed to CSE in vitro, as 
well as in rat lung tissue exposed to chronic cigarette smoke 
inhalation (Slebos et al 2007). Elevated levels of HO-1 were 
reported in the alveolar spaces of chronic smokers with 
and without COPD relative to nonsmokers (Maestrelli et al 
2001). Paradoxically, gene expression proﬁ  ling revealed 
that HO-1 gene expression was downregulated in lung tis-
sue from end stage COPD relative to healthy smokers (Ning 
et al 2004). This is consistent with reports that have shown 
decreased HO-1 expression in alveolar macrophages of 
severe COPD patients relative to those of smokers without 
lung function impairment (Maestrelli 2003). Furthermore, International Journal of COPD 2008:3(3) 368
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ex-smoking COPD patients were reported to have reduced 
HO-1 expression in alveolar macrophages relative to healthy 
ex-smokers (Slebos et al 2004). These preliminary observa-
tions indicate that stress protein responses such as HO-1 may 
be impaired during COPD progression, which may contribute 
to the etiology of this disease.
Recent studies have described a potential genetic basis 
for the HO-1 downregulation observed in COPD. A micro-
satellite (GT)n dinucleotide length polymorphism can occur 
in the promoter region of the ho-1 gene, resulting in a lower 
production of HO-1 in individuals that carry the long (L) 
allele [(GT)n  30] of this polymorphism (Yamada et al 
2000). This polymorphism was linked with the develop-
ment of COPD in a cohort of Japanese men (Yamada et al 
2000). In a retrospective study of French smokers the L allele 
[(GT)n  33] was associated with decreased lung function 
parameters relative to noncarriers. The greatest decline in 
lung function was observed in heavy smokers that carried 
the L allele (Guenegou et al 2006). These observations 
suggest that a genetically-dependent impairment of HO-1 
expression may occur in subpopulations, possibly linked to 
increased susceptibility to smoke-induced oxidative stress 
(Yamada et al 2000).
Concluding remarks
Several important limitations to gene expression analy-
ses using microarrays must be considered. For example, 
the number of lung tissue samples used for the assays is 
typically relatively small, which makes certain results 
based on one study not truly representative. Furthermore, 
the up or downregulation of specific genes may be differ-
ent or contradictory between studies. Additional studies 
on larger numbers of lung tissue samples are needed to 
validate the current findings and to address the variabil-
ity in the cellular composition of the tissues, given the 
heterogeneous nature of disease. More studies are also 
needed to determine the functions of these significantly 
changed genes in the pathogenesis of COPD, and to 
establish whether DNA sequence variation within these 
genes causes or predicts COPD.
Gene expression proﬁ  ling analyses (eg, microarray) to 
identify candidate genes important in the pathogenesis of 
COPD represent tour de force approaches in the current 
genomics era to better understand the pathogenesis of human 
disease such as COPD. However, we are just at the tip of 
the “iceberg” in that evolving state of the art approaches 
such as proteomics, metabolomics and gene polymorphism 
studies add to the total genomic armamentarium to better 
study the pathogenesis of COPD. Furthermore, laser capture 
microscopy of speciﬁ  c cell types in the lung can be used to 
obtain gene expression or protein data at a cellular level. 
Noninvasive methods to obtain human lung cells including 
exhaled breath condensate or sputum will provide exciting 
opportunities in the future. These approaches not only pro-
vide molecular signatures of COPD but also can serve as 
biomarkers to help in the diagnosis, treatment, outcome and 
response to therapy for COPD patients.
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